Compare Hims and Hers Health Inc (HIMS) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs KLA Corp. — how do they compare? Hims and Hers Health Inc trades at $30.88 (market cap $6.55B), while KLA Corp. trades at $195.9 (market cap $256.72B). The key difference: KLA Corp. is far larger — about 39.2× Hims and Hers Health Inc's market cap, and KLA Corp. pays a 0.47% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and KLA Corp. for 60 Days on average.
| HIMS | KLAC | |
|---|---|---|
Market Cap | $6.55B | $256.72B |
Volume | 14,842,814 | 9,970,753 |
Sector | Health | Technology |
52-Week High | $62.76 | $301.71 |
52-Week Low | $14.52 | $98.28 |
Typical Hold Time | 21 Days | 60 Days |
Enterprise Value | $7.25B | $257.97B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
KLA Corporation (KLAC) trades at $195.89, down 0.48% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $223.88. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.05 exceeding the $1.00 estimate, and maintains robust profitability with a net income margin of 35.57%. Revenue growth is supported by a $12.57 billion backlog driven by AI and advanced packaging demand, as highlighted in recent news.
The stock presents a compelling growth opportunity given its leadership in semiconductor process control and positive analyst sentiment, but elevated valuation ratios like a P/E of 53.75 pose risks if growth slows. Competition with Applied Materials and ASML, along with cyclical semiconductor industry exposure, requires monitoring. Institutional ownership trends and insider sales, such as CEO Richard Wallace's September 2026 transaction, add layers to the investment case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
